64 results about "Cholangeitis" patented technology

A compound of formula (I) wherein R<1> and R<2> are as defined in the description, R<2> being an aromatic group, useful in the treatment and condition selected from the group consisting of the group meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzeimer's disease, percussion injury, depression, atherosclerosis, osteoporosis in a mammal, including a human.

The invention discloses a traditional Chinese medicine composition for treating an autoimmune liver disease, and a preparation method thereof. The traditional Chinese medicine composition comprises the following medicinal raw materials in parts by weight: 15-30 parts of astragalus membranaceus, 10-30 parts of cooked rhubarb, 10-30 parts of glossy privet fruit, 10-30 parts of radix curcumae, 10-30 parts of large-leaved gentian, 10-30 parts of caulis spatholobi, 10-30 parts of caulis sinomenii, 10-30 parts of radix rubiae, 10-30 parts of sedum sarmentosum and 5-15 parts of liquorice. The traditional Chinese medicine has the effects of strengthening body resistance, detoxifying, dispersing stagnated liver qi for promoting bile flow, promoting blood circulation to remove blood stasis, expelling wind and removing dampness; the main treatment range comprises autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, and overlap syndrome of any two in the three diseases; and the traditional Chinese medicine composition has the treatment effects of restoring immune balance, inhibiting liver inflammation, protecting liver function, resisting hepatic fibrosis, improving clinical symptoms, improving survival quality and the like, and has high safety.

The invention discloses a Chinese medicine composition for treating an autoimmune liver disease. The Chinese medicine composition is prepared from the Chinese medicinal materials, namely rheum officinale, radix rubiae, fructus forsythia, herba siegesbeckiae, large-leaved gentian and liquorice. The invention also discloses a preparation method of the Chinese medicine composition and application of the Chinese medicine composition. The composition has the effects of clearing away heat and toxic materials, smoothing liver-gallbladder, and promoting blood circulation to remove blood stasis, and is mainly used for treating autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis.

The invention relates to suspension powder injection of cefamandole nafate and a preparation method thereof and further relates to new application of the injection in treating acute suppurative cholangitis. The frozen-dried suspension powder injection comprises the following components in parts by weight: 1 part of cefamandole nafate, 1.5-12 parts of surfactant and 2-15 parts of frozen-dried supporting agents.

The invention provides a cefetamet pivoxil hydrochloride submicron emulsion solid preparation, which comprises the following components in part by weight: 1 part of cefetamet pivoxil hydrochloride submicron emulsion grains, 0.4 to 3 parts of diluent, 0 to 0.5 part of disintegrating agent, 0 to 0.2 part of adhesive, 0 to 6 parts of flavoring agent, 0 to 0.4 part of aromatizer and 0 to 0.2 part of lubricant. The invention also discloses application of the preparation in preparation of a medicament for treating cholangitis, particularly acute pyogenic cholangitis.

The present invention relates to, inter alia, methods of treatment and combinations of (R)-2-(7-(4-cyclopentyl-3-(tri-fluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) useful for the treatment of primary biliary cholangitis (PBC). In some embodiments, the methods further comprise administering Compound 1, or a pharmaceutically salt, solvate, or hydrate thereof, in combination with a compound selected from the group consisting of: an antihistamine (diphenhydramine), cholestyramine (questran, prevalite), rifampin, an opioid antagonist (naloxone), pilocarpine (isopto carpine, salagen), cevimeline (evoxac), calcium and/or vitamin D supplement, and vitamin A, D, E and/or K supplement. Other embodiments, relate to titration packages for enabling compliance with a regimen of changing dosage of a medication over a period of time for the treatment of primary biliary cholangitis (PBC).

The invention relates to an application of an encoding gene ESRRA of an estrogen-related receptor alpha (ERR alpha) in preparation of a medicine for preventing or treating liver diseases. The liver diseases include non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), alcoholic fatty liver disease (AFLD), hepatic fibrosis, or cirrhosis. The adeno-associated virus is utilized to construct an ERRalpha overexpression vector system, and the fact that the ERR alpha gene and a delivery system of the ERR alpha gene can be used for preventing or treating the liver diseases is proved on various disease models.

The invention discloses application of prevotella in preparation of a medicine for treating cholestatic diseases. The cholestatic diseases include, but is not limited to, primary sclerosing cholangitis. After the inventor constructs a PSC animal model, it is determined that the abundance of P.copri in mice is consistently reduced in the same population, then intervention effects of P.copri on inflammation, fibrosis, cholestasis and the like of the PSC model are observed and evaluated through intragastric administration for one week and daily supplementation of 1*10<8> CFU of P.copri bacterial liquid, bile acid metabolism changes are determined through total bile acid determination and targeted bile acid detection analysis, and the action mechanism is analyzed. Experiments prove that the P.copri can obviously relieve cholestasis in hepatointestinal circulation of PSC mice and obviously improve liver fibrosis, which is of great significance to prevention or treatment of cholestatic diseases.

The invention relates to the technical field of medical equipment, in particular to a unilateral-wing bile-duct inner stent with a stent-withdrawing line. The unilateral-wing bile-duct comprises a tubular stent (1), a lateral wing (2) and the withdrawing line. The lateral-wing (2) is located at a near end of the stent (1). The withdrawing line is composed of a line (3) and a withdrawing rod (4), one end of the line (3) is tied to the middle of the withdrawing rod (4), while the other end of the same is fixed onto a far end of the stent (1). The unilateral-wing bile-duct stent is simple in structure and convenient to use, so that withdrawing or replacing the stent is facilitated. The line of the drawing line is thin, so that a barrier function of the duodenal papilla cannot be affected, intestinal bacteria can be prevented from retrograding to enter the bile duct to cause cholangitis, the intestinal bacterial can also be prevented from attaching to an inner wall of the stent or blocking the stent due to food reflux, and bleeding, perforating and retrograde bile-duct infection and the like caused by the fact that the duodenal papilla is needed to be cut open since the stent fails to be withdrawn are avoided.

The invention relates to the treatment of ascites, and especially refractory ascites, with an orally bioavailable prodrug of dopamine. A preferred prodrug of dopamine is docarpamine. In one embodiment treated patients are, prior to treatment, on doses of furosemide >80 mg/day and/or spironolactone >100 mg/day or equivalent doses of an alternative loop-acting and/or distal-acting diuretic. The ascites treated by the invention are typically caused by liver cirrhosis due to alcohol or non-alcoholic fatty liver disease and generally not due to viral hepatitis or primary biliary cholangitis. Preferred dosing is greater that 2250 mg per day, with more preferred doses exceeding 3500 mg per day.

The invention discloses a traditional Chinese medicine combination for treating hepatobiliary diseases and a preparation method thereof. The traditional Chinese medicine combination is composed of the following raw materials, by weight, of 200-300 parts of ganoderma lucidum soak solutions, 30-60 parts of antrodia camphorata polysaccharide, 70-100 parts of selenium-enriched pleurotus ostreatus fruiting body powder, 10-20 parts of bear bile powder, 100-200 parts of panax notoginseng powder, 80-120 parts of rock candies and 180-220 parts of tilia honey. The traditional Chinese medicine combination has good curative effect on treating liver cirrhosis, viral hepatitis type B, cholangitis, gallstones, a bile duct cancer and a gallbladder cancer.

The invention discloses a molecular marker for diagnosing primary biliary cholangitis and application thereof. According to the present invention, the anti-human multimer immunoglobulin receptor antibody is adopted as the primary biliary cholangitis diagnosis molecular marker so as to prepare the diagnosis reagent; the human multimer immunoglobulin receptor antibody is remarkably increased in serum of PBC AMA-M2 subtype positive and negative patients, which indicates that in the attack of PBC, the serum anti-human multimer immunoglobulin receptor antibody specifically targets human multimer immunoglobulin receptors on small and medium bile ducts in the liver, thereby causing damage to the small and medium bile ducts. According to the invention, a new explanation is provided for the pathogenesis of the PBC, and in addition, a new means is provided for the specific diagnosis of the PBC by detecting the level of the serum anti-human multimeric immune globulin receptor antibody. The method is simple and reliable, materials are convenient to obtain, and the method has great application value in PBC diagnosis.

The invention discloses a composition for treating hepatitis-cholangitis overlap syndrome by using Yunnan paris polyphylla as a main raw material as well as a preparation method, a preparation and application of the composition. The composition for treating the hepatitis-cholangitis overlap syndrome by taking the Yunnan rhizoma paridis as the main raw material is prepared from the following raw materials in parts by weight: 1000 to 2500 parts of herba artemisiae scopariae, 500 to 1500 parts of rhizoma paridis, 1000 to 3000 parts of radix paeoniae rubra, 300 to 1500 parts of scorpio, 1000 to 2000 parts of pericarpium citri reticulatae viride, 1000 to 2000 parts of radix aucklandiae, 1000 to 3000 parts of rhizoma smilacis glabrae, 1000 to 2500 parts of cortex dictamni, 1000 to 3000 parts of malt and 500 to 1500 parts of liquorice root. The preparation can be granules, tablets, capsules, oral solutions and syrups. The application refers to the application of the composition for treating the hepatitis-cholangitis overlap syndrome by taking the Yunnan paris polyphylla as the main raw material in preparing a medicine for treating the hepatitis-cholangitis overlap syndrome.

The invention relates to a biomarker for diagnosing primary sicca syndrome and application of the biomarker. According to the biomarker for diagnosing primary sicca syndrome and application of the biomarker of the invention, a lectin microarray containing 56 types of lectins is adopted to detect a glycan spectrum of specific binding of the serum IgG and the lectin of a patient with the primary sicca syndrome (PSS). The results show that LCA lectin binding glycan content is increased in the patient with primary biliary cholangitis (PBC) compared with that of a healthy person. As the LCA lectin is specific binding fucose, the expression of the fucose level in the patient withPSS is increased. A lectin immunoblotting verification result shows that the content of the LCA lectin binding glycan is still increased in the patient with the PSS. Therefore, the LCA lectin binding glycan level in the serum IgG can be used as a marker of the primary sicca syndrome (PSS).

The invention relates to the use of pharmaceutical compositions of the SGLT2 inhibitor, remogliflozin etabonate, to treat primary sclerosing cholangitis (PSC). Methods and compositions associated with the invention can improve or maintain clinical outcomes of PSC symptoms, such as ascites accumulation, hepatic encephalopathy, development of varices, jaundice, variceal bleeding, cholangiocarcinoma, hepatocellular carcinoma, evidence of cirrhosis, and colorectal cancer.

The invention discloses application of polypeptide AT03 in a medicine used for treating primary biliary cholangitis. The amino acid sequence of the polypeptide AT03 is Val-His-Val-Val-R1, wherein R1 is -NH2. A large number of experimental studies prove that the polypeptide AT03 has a treatment effect on a common bile duct-ligated rat cholestatic liver cirrhosis model, and the treatment effect is specifically shown in that liver cholestasis, intrahepatic biliary obstruction, liver cell injury and liver tissue fibrosis process can be improved; and the polypeptide AT03 can be used for preparing the medicine used for treating primary biliary cholangitis.

The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholgangitis, dyslipidenmia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

The invention provides an endobiliary drainage tube for preventing duodenal papilla bleeding. The endobiliary drainage tube comprises a drainage tube body, an inner core and a propeller, wherein at least two side holes are formed in the head tube section of the drainage tube body, a cylindrical balloon is attached to the middle tube section of the drainage tube body, a one-way injection valve is arranged in the tail tube section of the drainage tube body, and the head of the injection valve is communicated with the balloon; the balloon is cylindrical after being filled; the head of the inner core comprises a channel I and a needle tube, the channel I is arranged in a tube cavity of the drainage tube body and penetrates out, and the needle tube penetrates through the tail end of the injection valve; the tail part of the inner core is positioned in a pipe cavity of the propeller; the tail part comprises a channel II communicated with the channel I and a channel III communicated with theneedle tube; a channel IV communicated with the channel II and a channel V communicated with the channel III are arranged in the base of the inner core; and the channel V is connected with a balloon injection joint. While bile is drained, the filled balloon can press the duodenal papilla sphincter, and postoperative cholangitis and duodenal papilla bleeding can be prevented.